Page 74 - Eceptor News Today

Scientists at Dana-Farber Cancer Institute have developed a drug that potently neutralizes SARS-CoV-2, the COVID-19 coronavirus, and is equally effective against the Omicron variant and every other tested variant.

In light of the recent pandemic, people across the globe are increasingly becoming aware of the importance of consistent high-quality nutrition and daily exercise.

A UCLA Jonsson Comprehensive Cancer Center researcher and collaborators in a multicenter study will present updated results and plans for further research on a new approach to treating advanced ER-positive/HER2-negative breast cancer.

Nearly three years into the pandemic, many of us now carry antibodies against the virus-;due to an infection or two, a few doses of mRNA vaccine, or a round of monoclonal-antibody treatment.

Among premenopausal women with hormone receptor (HR)-positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on a genomic assay called Breast Cancer Index (BCI) had increased risk of distant recurrence, and those with low BCI benefited more from the addition of ovarian suppression therapy to endocrine therapy after 12 years of follow-up, according to data presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole and 63 percent in combination with anastrozole, according to results from the phase II TRIO-US B-12 TALENT trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

In this interview, Ryan Muise talks to AZoNetwork about the added value of using flow cytometry in CAR T-Cell clinical trials.

Researchers evaluated blood plasma proteins to identify new targets for COVID-19 treatment approaches and prevent complications associated with severe illness.

Researchers developed an mRNA technology-based vaccine candidate against the monkeypox virus and evaluated its immunogenicity in animal models.

In this special supplement to the Journal of Parkinson's Disease, "The Immune System in Parkinson's Disease," experts highlight the latest research breakthroughs on the links between immune activation and neuroinflammation and Parkinson's disease (PD) and discuss the challenges and novel therapeutic strategies targeting the immune system with the hope of reducing or reversing neurodegeneration.